BBOT (BridgeBio Oncology Therapeutics) EBIT per Share: $-2.63 (TTM As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics EBIT per Share?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 EBIT per Share is $-2.63 as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100. Among 1,173 Biotechnology companies, BridgeBio Oncology Therapeutics ranks worse than 85251.41% on this metric.

BridgeBio Oncology Therapeutics's EBIT per Share for the three months ended in Mar. 2026 was $-0.58. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.63.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BridgeBio Oncology Therapeutics's EBIT per Share or its related term are showing as below:

BBOT's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

BridgeBio Oncology Therapeutics's EBIT for the three months ended in Mar. 2026 was $-46.18 Mil.

BridgeBio Oncology Therapeutics  (NAS:BBOT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BridgeBio Oncology Therapeutics EBIT per Share Related Terms

BridgeBio Oncology Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics EBIT per Share Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
EBIT per Share
-0.82 -1.02 -4.68

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.29 -0.38 -1.13 -0.54 -0.58
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BridgeBio Oncology Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-145.819/31.145
=-4.68

BridgeBio Oncology Therapeutics's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-46.179/80.032
=-0.58

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-2.63 mean?
BridgeBio Oncology Therapeutics (BBOT) has a EBIT per Share of $-2.63 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 1173 companies in the Biotechnology industry.
Is BridgeBio Oncology Therapeutics' EBIT per Share too high?
BridgeBio Oncology Therapeutics' current EBIT per Share is $-2.63. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' EBIT per Share compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 1173 companies for EBIT per Share. This places BridgeBio Oncology Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BridgeBio Oncology Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Oncology Therapeutics's current EBIT per Share is $-2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current EBIT per Share of $-2.63. The current EBIT per Share is $-2.63. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current EBIT per Share is $-2.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price